Food Drug and Administration approved a second drug for HIV-1 preexposure prophylaxis. The name of the drug is Doscovy that is prepared with the combination of emtricitabine and tenofovir alafenamide, 200 mg, and 25 mg, respectively.
It reduces the risk of HIV infection from sex in which receptive vaginal sex is also included. It is specially made for adults and adolescents who weight 35 kg (77lb).
FDA said, “ Descovy medicine is the second drug that does not indicate the individuals at risk for the HIV-1 infection.
The Federal Advisory panel objected to Gilead Sciences in August for the approval for preexposure prophylaxis. According to Medscape Medical News, the drug is not effective for women.
According to the FDA panel, “ Descovy is safe and effective for PrEP against HIV infection in men and transgender women having sex with men.
However, the FDA panel also indicates cisgender women.
Cisgender women denote people who correspond with their birth sex.
It is one of the approved medicine in the United States against HIV-1 infection for adults and pediatric patients.
Descovy efficacy and safety were evaluated in a randomized and double-blind trial in which HIV negative men and transgender women were included, and they all were on the risk of HIV-1 infection.
The prosecution was compared daily with the fixed dosage of approved drug emtricitabine and tenofovir diisopropyl fumarate. They both passed in 2012 for PrEP. It was followed for 48 to 96 weeks.
The trial showed the beneficial effects and reduced the risk of pf acquiring HIV-1 infection. One of the common side effects of Descovy is Diarrhea that was shown in the participants.
It is a warning for people who are suffering from hepatitis B virus. People who have unknown or positive HIV-1 status should not take Descovy. It is only prescribed for HIV negative patients before and after every three months.
FDA’s Deputy Director of the Division of Antiviral Products, Jeffrey Murray, MD, MPH, said, “ PrEP is very effective and can prevent HIV infection, he declared all with the news of the approval.
Moreover, he also added that the approval of Descovy would permit to prevent the risk of HIV infections.”